Evogene, Systasy and LMU University Hospital Munich team up on AI-driven drug discovery for inflammatory diseases

A new international collaboration backed by a pan-European EUREKA grant aims to develop targeted small-molecule therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). Evogene (Nasdaq: EVGN), Systasy Bioscience, and LMU University Hospital Munich announced the partnership on Feb. 11, with additional participation from the Weizmann Institute of Science. The… The post Evogene, Systasy and LMU University Hospital Munich team up on AI-driven drug discovery for inflammatory diseases appeared first on Drug Discovery and Development.

Continue reading →